Rayner
Geoff Allan has a diverse work experience spanning over several industries. Geoff is currently serving as the Group Chief Financial Officer at Rayner starting from April 2023. Prior to this, they held the position of Chief Financial Officer at HRA Pharma from November 2011 to January 2023. In this role, they successfully led the global finance organization, driving revenue and margin growth in a demanding LBO environment. Geoff also played a crucial role in M&A activity and the establishment of a Joint Venture in China.
Before HRA Pharma, Geoff served as the Chief Financial Officer - Kewego at Piksel from 2007 to 2011. Geoff was involved in building and leading the international finance and administration organization during the company's growth phase. In addition, they played a key role in the successful sale of Kewego to a US Nasdaq listed company, which is now known as Piksel.
Geoff Allan's earlier experiences include serving as Secrétaire générale at le Jardin des Fleurs, Managing Director at TAJAN Auction House, Chief Financial Officer at eDevice, Assistant to the Chairman at GROUPE ROUSSELET, Assistant to the Chairman at NOVALLIANCE, Assistant Manager 2VP at The Chase Manhattan Bank, and Assistant Manager at Elysée Investissements.
Geoff Allan's education history includes attending several institutions from 1976 to 1986. Geoff started their education at George Watson's College, where they pursued a non-degree program from 1976 to 1981. Later, from 1981 to 1982, they attended Stevenson College Edinburgh, where they did not pursue a specific degree or field of study.
Subsequently, from 1982 to 1984, Geoff Allan studied at King's College London, earning a Bachelor of Laws (LLB) degree with a focus on law. Finally, from 1984 to 1986, they attended the University of Paris I: Panthéon-Sorbonne, where they obtained a Maitrise degree in law.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.